Outcomes of ketorolac versus depomedrol infiltrations for subacromial impingement syndrome: a randomized controlled trial

被引：6
作者：
Goyal T. [1 ]
Paul S. [1 ]
Sethy S.S. [1 ]
Choudhury A.K. [1 ]
机构：
[1] Department of Orthopaedics, All India Institute of Medical Sciences, AIIMS, Virbhadra Marg, Uttarakhand, Rishikesh
来源：
MUSCULOSKELETAL SURGERY | 2022年 / 106卷 / 1期
关键词：
Ketorolac; Nonsteroidal anti-inflammatory drugs; Shoulder pain; Steroid injections; Subacromial impingement; Subacromial injection;
D O I：
10.1007/s12306-020-00667-7
中图分类号：
学科分类号：
摘要：
Purpose: Local subacromial infiltration with steroids is a common method of treatment of subacromial impingement syndrome. However, the use of steroids has concerns like tendon rupture, articular cartilage changes and infections. Local NSAIDs infiltration has recently been tried in literature. This study compares the effect of subacromial injections of ketorolac with steroids. Methods: A randomized controlled study was planned with 35 patients in each group. Patients in group-1 were infiltrated with subacromial ketorolac (60 mg with 2% lignocaine) and in group-2 with a steroid (methylprednisolone-40 mg with 2% lignocaine). A similar rehabilitation protocol was followed, and clinical outcomes were analyzed using visual analog scale (VAS) for pain and shoulder pain and disability score (SPADI) and range of motion at one-month and three-months follow-up. Results: Total data of 67 patients were analyzed, as three patients were lost to follow-up. In group 1, mean VAS improved from 7.9 ± 0.95 to 3.19 ± 0.81 (p < 0.001) and SPADI improved from 61.41 ± 11.86 to 28.91 ± 9.06 (p < 0.001) at three months, respectively. In group 2, mean VAS improved from 8.05 ± 0.94 to 2.9 ± 0.64 (p < 0.001) and SPADI improved from 63.45 ± 9.64 to 25.32 ± 6.87 (p < 0.001) at three months, respectively. However, there were no differences in functional outcomes between the groups (p = 0.21 for VAS, p = 0.16 for SPADI). Conclusion: Subacromial ketorolac infiltration has an equivalent outcome as that of steroid infiltration. Ketorolac could be considered as a reasonable alternative to steroids in cases where it is contraindicated. © 2020, Istituto Ortopedico Rizzoli.
引用
收藏
页码：29 / 34
页数：5
相关论文
共 32 条
  • [1] Alvarez C.M., Litchfield R., Jackowski D., Griffin S., Kirkley A., A prospective, double-blind, randomized clinical trial comparing subacromial injection of betamethasone and xylocaine to xylocaine alone in chronic rotator cuff tendinosis, Am J Sports Med, 33, 2, pp. 255-262, (2005)
  • [2] Van der Windt D.A., Koes B.W., de Jong B.A., Bouter L.M., Shoulder disorders in general practice: incidence, patient characteristics, and management, Ann Rheum Dis, 54, 12, pp. 959-964, (1995)
  • [3] Adebajo A.O., Nash P., Hazleman B.L., A prospective double blind dummy placebo controlled study comparing triamcinolone hexacetonide injection with oral diclofenac 50 mg TDS in patients with rotator cuff tendinitis, J Rheumatol, 17, 9, pp. 1207-1210, (1990)
  • [4] Morrison D.S., Frogameni A.D., Woodworth P., Non-operative treatment of subacromial impingement syndrome, JBJS, 79, 5, pp. 732-737, (1997)
  • [5] Garvey K.D., Solberg M.J., Cai A., Matzkin E.G., Efficacy of corticosteroid injection for subacromial impingement syndrome, Ann Joint, 3, (2018)
  • [6] Buchbinder R., Green S., Youd J.M., Corticosteroid injections for shoulder pain, Cochrane Database Syst Rev, 1, (2003)
  • [7] Brinks A., Koes B.W., Volkers A.C., Verhaar J.A., Bierma-Zeinstra S.M., Adverse effects of extra-articular corticosteroid injections: a systematic review, BMC Musculoskelet Disord, 11, 1, (2010)
  • [8] Park S.K., Choi Y.S., Kim H.J., Hypopigmentation and subcutaneous fat, muscle atrophy after local corticosteroid injection, Korean J Anesthesiol, 65, (2013)
  • [9] Halpern A.A., Horowitz B.G., Nagel D.A., Tendon ruptures associated with corticosteroid therapy, West J Med, 127, 5, (1977)
  • [10] Taheri P., Dehghan F., Mousavi S., Solouki R., Comparison of subacromial ketorolac injection versus corticosteroid injection in the treatment of shoulder impingement syndrome, J Res Pharm Pract, 1, 6, (2017)
1234